Evusheld (Tixagevimab and Cilgavimab) for the Pre-exposure Prophylaxis of COVID-19 in Adults and Adolescents (≥ 12 Years of Age and Weighing at Least 40 kg)


( Last Updated : April 21, 2022)
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HD0008-000

Details


Tixagevimab and cilgavimab (Evusheld) is a combination of long-acting monoclonal antibodies for intramuscular administration that provides pre-exposure prophylaxis against COVID-19 for people at risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who have not had a known recent exposure to an individual infected with SARS-CoV-2. CADTH conducted a review of the evidence and convened an Implementation Advice Panel to prioritize the patient populations that are most likely to benefit from pre-exposure prophylaxis with Evusheld.